DDRD (DNA Damage Response Deficiency)

Almac’s Predictive Assay for DNA Damaging Agents

Almac has developed a gene expression assay to detect DNA damage response deficient tumors associated with loss of the FA/BRCA pathway. These tumours have been shown to benefit from DNA damaging agents such as anthracycline based chemotherapy.

This assay can predict outcomes following treatment with:

  1. DNA damaging drugs such as Anthracycline and Cyclophosphamide
  2. Novel DNA-damaging therapeutics such as PARP inhibitors

The DDRD assay was originally developed for use in early stage breast cancer but is currently being validated in other disease areas such as ovarian, esophageal and colorectal cancers.

 

Almac’s DDRD assay has the potential to be used as a companion diagnostic for DNA damaging therapy across a range of disease areas.

Contact Us

Related resources

  • Publications

    Identification and Validation of an Anthracycline / Cyclophosphamide–Based Chemotherapy Response Assay

    Learn more
  • News

    Almac publishes breast cancer chemotherapy response assay in the Journal of the National Cancer Institute

    Learn more
  • Poster

    DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer

    Learn more
  • Poster

    Identification of a novel breast cancer molecular subgroup associated with a deficiency in DNA-damage response

    Learn more
  • Poster

    Impact of DNA Repair Deficiency Signature on Outcomes in Triple Negative Breast Cancer (TNBC) Patients Treated with AC Chemotherapy

    Learn more
  • Poster

    Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Esophageal and Gastric Adenocarcinoma

    Learn more